Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06178978 · ClinicalTrials.gov registry record
Device for Age-related Macular Degeneration (AMD)
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 31
- Enrollment target
NCT06178978: Completed study, sponsored by University of Michigan.
NCT06178978 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06178978 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
Study Summary
This study involves user acceptability and feedback of KalEYEdoscope, a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration (AMD).
Primary Outcome
Obtain user feedback via a questionnaire and evaluate the usability of using this device.
Interventions
- DEVICE KalEYEdoscope
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-03-10 |
| Est. Completion | 2022-03-25 |
What the finished NCT06178978 record still lists
NCT06178978 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 31 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which KalEYEdoscope is the first listed.
NCT06178978 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06178978 about?
NCT06178978 is a clinical study titled "Device for Age-related Macular Degeneration (AMD)". This study involves user acceptability and feedback of KalEYEdoscope, a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration (AMD).
What is the current status of trial NCT06178978?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2022-03-10. Estimated completion is 2022-03-25.
What interventions are being tested in trial NCT06178978?
The interventions under investigation include: KalEYEdoscope (DEVICE).
Who is sponsoring clinical trial NCT06178978?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI